Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

Treatment of osteoporosis with denosumab, compared with bisphosphonate therapy, may help prevent progression to type 2 diabetes (T2D) in those at high risk for it. In patients with osteoporosis who ...

Biosimilar CT-P41 showed comparable efficacy and safety to reference denosumab for treating osteoporosis among postmenopausal women. CT-P41, a biosimilar candidate for denosumab, demonstrates efficacy ...

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

Continued denosumab treatment is associated with a lower risk for diabetes in adults with osteoporosis older than 65 years, found a large-scale cohort study in Taiwan. Denosumab, used in osteoporosis ...

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...

Continued treatment with the osteoporosis drug denosumab (Prolia) was tied to a lower risk of developing diabetes in a Taiwanese cohort study. In a propensity score-matched analysis, adherence to ...

BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti ® (denosumab subcutaneous injection, ...

In patients on dialysis, the use of an injectable monoclonal antibody for prevention of osteoporosis-related fractures may increase the risk of MACE compared with oral bisphosphonates, observational ...